These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33988991)

  • 1. Factors Governing Selectivity of Dopamine Receptor Binding Compounds for D2R and D3R Subtypes.
    Hayatshahi HS; Luedtke RR; Taylor M; Chen PJ; Blass BE; Liu J
    J Chem Inf Model; 2021 Jun; 61(6):2829-2843. PubMed ID: 33988991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor.
    Newman AH; Beuming T; Banala AK; Donthamsetti P; Pongetti K; LaBounty A; Levy B; Cao J; Michino M; Luedtke RR; Javitch JA; Shi L
    J Med Chem; 2012 Aug; 55(15):6689-99. PubMed ID: 22632094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors.
    Michino M; Donthamsetti P; Beuming T; Banala A; Duan L; Roux T; Han Y; Trinquet E; Newman AH; Javitch JA; Shi L
    Mol Pharmacol; 2013 Dec; 84(6):854-64. PubMed ID: 24061855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor.
    Adhikari P; Xie B; Semeano A; Bonifazi A; Battiti FO; Newman AH; Yano H; Shi L
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33924613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and evaluation of bitopic arylpiperazinephenyl-1,2,4-oxadiazoles as preferential dopamine D3 receptor ligands.
    Cao Y; Min C; Acharya S; Kim KM; Cheon SH
    Bioorg Med Chem; 2016 Jan; 24(2):191-200. PubMed ID: 26707842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism.
    Lane JR; Abramyan AM; Adhikari P; Keen AC; Lee KH; Sanchez J; Verma RK; Lim HD; Yano H; Javitch JA; Shi L
    Elife; 2020 Jan; 9():. PubMed ID: 31985399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of bitopic ligands based on fallypride and evaluation of their affinity and selectivity towards dopamine D
    Tian GL; Hsieh CJ; Taylor M; Lee JY; Riad AA; Luedtke RR; Mach RH
    Eur J Med Chem; 2023 Dec; 261():115751. PubMed ID: 37688938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for a Stereoselective Mechanism for Bitopic Activity by Extended-Length Antagonists of the D
    Moritz AE; Bonifazi A; Guerrero AM; Kumar V; Free RB; Lane JR; Verma RK; Shi L; Newman AH; Sibley DR
    ACS Chem Neurosci; 2020 Oct; 11(20):3309-3320. PubMed ID: 32969645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors.
    Lane JR; Chubukov P; Liu W; Canals M; Cherezov V; Abagyan R; Stevens RC; Katritch V
    Mol Pharmacol; 2013 Dec; 84(6):794-807. PubMed ID: 24021214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors.
    Verma RK; Abramyan AM; Michino M; Free RB; Sibley DR; Javitch JA; Lane JR; Shi L
    PLoS Comput Biol; 2018 Jan; 14(1):e1005948. PubMed ID: 29337986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Filtering out Low-Affinity Bitropic Ligands for Dopamine Receptors Based on Ligand Conformation.
    Hayatshahi HS; Liu J
    ACS Chem Neurosci; 2020 Sep; 11(17):2523-2527. PubMed ID: 32786308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leveraging a Low-Affinity Diazaspiro Orthosteric Fragment to Reduce Dopamine D
    Reilly SW; Riad AA; Hsieh CJ; Sahlholm K; Jacome DA; Griffin S; Taylor M; Weng CC; Xu K; Kirschner N; Luedtke RR; Parry C; Malhotra S; Karanicolas J; Mach RH
    J Med Chem; 2019 May; 62(10):5132-5147. PubMed ID: 31021617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of arylpiperazine-reverse amides as biased dopamine D3 receptor ligands.
    Cao Y; Paudel S; Zhang X; Kim KM; Cheon SH
    Bioorg Med Chem; 2015 Sep; 23(17):5264-72. PubMed ID: 26278029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Dopamine D3-Selective Receptor Ligands Containing a 6-Methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol Motif.
    Gadhiya S; Cordone P; Pal RK; Gallicchio E; Wickstrom L; Kurtzman T; Ramsey S; Harding WW
    ACS Med Chem Lett; 2018 Oct; 9(10):990-995. PubMed ID: 30344905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current drug treatments targeting dopamine D3 receptor.
    Leggio GM; Bucolo C; Platania CB; Salomone S; Drago F
    Pharmacol Ther; 2016 Sep; 165():164-77. PubMed ID: 27343365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatic linker variations in novel dopamine D
    Di Biase C; Leitzbach L; Frank A; Zivkovic A; Stark H
    Arch Pharm (Weinheim); 2024 Aug; 357(8):e2400071. PubMed ID: 38736025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.
    Zou MF; Keck TM; Kumar V; Donthamsetti P; Michino M; Burzynski C; Schweppe C; Bonifazi A; Free RB; Sibley DR; Janowsky A; Shi L; Javitch JA; Newman AH
    J Med Chem; 2016 Apr; 59(7):2973-88. PubMed ID: 27035329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the dopamine D3 receptor: an overview of drug design strategies.
    Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V
    Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure Activity Relationships for a Series of Eticlopride-Based Dopamine D
    Shaik AB; Boateng CA; Battiti FO; Bonifazi A; Cao J; Chen L; Chitsazi R; Ravi S; Lee KH; Shi L; Newman AH
    J Med Chem; 2021 Oct; 64(20):15313-15333. PubMed ID: 34636551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity.
    Banala AK; Levy BA; Khatri SS; Furman CA; Roof RA; Mishra Y; Griffin SA; Sibley DR; Luedtke RR; Newman AH
    J Med Chem; 2011 May; 54(10):3581-94. PubMed ID: 21495689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.